Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study.

Abstract

BACKGROUND:

Beta-lactam therapeutic drug monitoring (BL TDM; drug level testing) can facilitate improved outcomes in critically ill patients. However, only 10%-20% of hospitals have implemented BL TDM. This study aimed to characterize provider perceptions and key considerations for successfully implementing BL TDM.

METHODS:

This was a sequential mixed-methods study from 2020 to 2021 of diverse stakeholders at 3 academic medical centers with varying degrees of BL TDM implementation (not implemented, partially implemented, and fully implemented). Stakeholders were surveyed, and a proportion of participants completed semistructured interviews. Themes were identified, and findings were contextualized with implementation science frameworks.

RESULTS:

Most of the 138 survey respondents perceived that BL TDM was relevant to their practice and improved medication effectiveness and safety. Integrated with interview data from 30 individuals, 2 implementation themes were identified: individual internalization and organizational features. Individuals needed to internalize, make sense of, and agree to BL TDM implementation, which was positively influenced by repeated exposure to evidence and expertise. The process of internalization appeared more complex with BL TDM than with other antibiotics (ie, vancomycin). Organizational considerations relevant to BL TDM implementation (eg, infrastructure, personnel) were similar to those identified in other TDM settings.

CONCLUSIONS:

Broad enthusiasm for BL TDM among participants was found. Prior literature suggested that assay availability was the primary barrier to implementation; however, the data revealed many more individual and organizational attributes, which impacted the BL TDM implementation. Internalization should particularly be focused on to improve the adoption of this evidence-based practice.

• Authors: Erin F Barreto, Pooja N Chitre, Kathleen H Pine, Kathryn K Shepel, Andrew D Rule, Mohammad H Alshaer, Mohd Hafiz Abdul Aziz, Jason A Roberts, Marc H Scheetz, Sara E Ausman, Lindsay N Moreland-Head, Christina G Rivera, Paul J Jannetto, Kristin C Mara, Kasey R Boehmer
• Journal: Therapeutic drug monitoring (Ther Drug Monit) Vol. 45 Issue 4 Pg. 508-518 (08 01 2023) ISSN: 1536-3694 [Electronic] United States
• PMID: 37076424 (Publication Type: Multicenter Study, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• beta-Lactams
• Anti-Bacterial Agents
• Vancomycin

Topics

• Humans
• beta-Lactams (therapeutic use)
• Drug Monitoring (methods)
• Critical Illness
• Anti-Bacterial Agents (therapeutic use)
• Vancomycin (therapeutic use)